Prothena Corporation PLC

PRTA

Equity

ISIN IE00B91XRN20 / Valor 20224443

NASDAQ (2026-04-24)

USD 10.75+0.19%

Prothena Corporation PLC
UMushroom community rating:

3.84 7 votes No rating yet

NegativeNeutralPositive

About company

Prothena Corporation PLC is a biotechnology firm focused on the late-stage clinical development of treatments for neurodegenerative and rare peripheral amyloid diseases. Leveraging its expertise in protein dysregulation, the company has developed a diverse pipeline of investigational therapies aimed at addressing the complex challenges of neurological dysfunction and misfolded proteins. Prothena's approach combines internal discovery with strategic collaborations across academia and the industry to advance its portfolio of novel therapeutic solutions. Founded from the legacy of Athena Neurosciences and established as an independent entity in December 2012, Prothena trades on the Nasdaq Global Select Market under the symbol "PRTA." The company's commitment to innovation is rooted in its history of significant scientific contributions, including discoveries that have advanced the understanding of Alzheimer’s disease and the development of FDA-approved treatments for multiple sclerosis.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

11.4%1Y

-80.4%3Y

-54.8%5Y

Performance

61.5%1Y

66.8%3Y

73.2%5Y

Volatility